Expression and Analysis of Rsf-1 and P16 in Cervical Intraepithelial Neoplasia

Objective: The molecular mechanism in the occurrence and progression of cervical intraepithelial neoplasia (CIN) is of great theoretical significance to improve the early diagnosis, treatment and prognostic judgement of CIN in clinical practice. The current study aimed to detect the expression of remodel and space factor-1 (Rsf-1) and P16 in CIN, and to analyze the expression of Rsf-1 and P16 in different stages of CIN and to investigate the possible correlation. Methods: A total of 110 samples of CIN were collected from the Department of Pathology, the First Affiliated Hospital of Bengbu Medical College in 2018. Rsf-1 and P16 was detected by immunohistochemical staining in pathological tissue sections. The correlation between Rsf-1 expression and P16 expression in CIN was further analyzed. Results: The immunohistochemical results of 110 cases of CIN showed that the positive rate of P16 and Rsf-1 gradually increases with the grade of CIN increases. The expression of P16 was significantly different between different CIN grade (p = 0.011). The expression of Rsf-1 was also significantly different in different CIN grade (p = 0.015). Conclusions: Rsf-1 and P16 was highly expressed or over-expressed in high-grade CIN, and the positive rate of their expression increased with the increase in CIN grade.

Rsf-1; P16; cervical intraepithelial neoplasia; immunohistochemistry

[1] van der Horst J, Siebers AG, Bulten J, Massuger LF, de Kok IM. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004–2013. Cancer Medicine. 2017; 6: 416–423.

[2] Wang X, Sheu JJ, Lai M, Yin-Yi Chang C, Sheng X, Wei L, et al. RSF-1 overexpression determines cancer progression and drug resistance in cervical cancer. BioMedicine. 2019; 8: 4.

[3] Curty G, de Carvalho PS, Soares MA. The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. International Journal of Molecular Sciences. 2019; 21: 222.

[4] Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis. Archives of Gynecology and Obstetrics. 2020; 302: 1329–1337.

[5] Dijkstra MG, Snijders PJF, Arbyn M, Rijkaart DC, Berkhof J, Meijer CJLM. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Annals of Oncology. 2014; 25: 927–935.

[6] Mitra A, Tzafetas M, Lyons D, Fotopoulou C, Paraskevaidis E, Kyrgiou M. Cervical intraepithelial neoplasia: screening and management. British Journal of Hospital Medicine. 2016; 77: C118–C123.

[7] Hoffman SR, Le T, Lockhart A, Sanusi A, Dal Santo L, Davis M, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review. International Journal of Cancer. 2017; 141: 8–23.

[8] Clifford GM, Tully S, Franceschi S. Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: a Meta-Analysis from HPV Infection to Cervical Cancer. Clinical Infectious Diseases. 2018; 64: 1228–1235.

[9] Sichero L, Rollison DE, Amorrortu RP, Tommasino M. Beta Human Papillomavirus and Associated Diseases. Acta Cytologica. 2019; 63: 100–108.

[10] Feng M, Duan R, Gao Y, Zhang H, Qiao Y, Li Q, Zhao F. Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Cervical Intraepithelial Neoplasia in Chinese Women Living With HIV. Frontiers in Cellular and Infection Microbiology. 2021; 11: 703259.

[11] Tingting C, Shizhou Y, Songfa Z, Junfen X, Weiguo L, Xiaodong C, et al. Human papillomavirus 16E6/E7 activates autophagy via Atg9B and LAMP1 in cervical cancer cells. Cancer Medicine. 2019; 8: 4404–4416.

[12] Minoni L, Romero-Medina MC, Venuti A, Sirand C, Robitaille A, Altamura G, et al. Transforming Properties of Beta-3 Human Papillomavirus E6 and E7 Proteins. MSphere. 2020; 5: e00398–20.

[13] Loyola A, Huang J, LeRoy G, Hu S, Wang Y, Donnelly RJ, et al. Functional analysis of the subunits of the chromatin assembly factor RSF. Molecular and Cellular Biology. 2003; 23: 6759–6768.

[14] Chen X, Sun X, Guan J, Gai J, Xing J, Fu L, et al. Rsf-1 Influ-ences the Sensitivity of Non-Small Cell Lung Cancer to Pacli-taxel by Regulating NF-κB Pathway and its Downstream Proteins. Cellular Physiology and Biochemistry. 2017; 44: 2322–2336.

[15] Wu X, Chen Y, Guo W, Li T, Dong H, Wang W, et al. HMGB1 regulates SNAI1 during NSCLC metastasis, both directly, through transcriptional activation, and indirectly, in a RSF1-IT2-dependent manner. Molecular Oncology. 2020; 14: 1348–1364.

[16] Cai G, Yang Q, Sun W. RSF1 in cancer: interactions and functions. Cancer Cell International. 2021; 21: 315.

[17] Li M, Yang J, Liu K, Yang J, Zhan X, Wang L, et al. P16 promotes proliferation in cervical carcinoma cells through CDK6-HuR-IL1a axis. Journal of Cancer. 2020; 11: 1457–1467.

[18] Li P, Zhang X, Gu L, Zhou J, Deng D. P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib. PLoS ONE. 2019; 14: e0223084.

[19] Horn L, Handzel R, Borte G, Siebolts U, Haak A, Brambs CE. Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma. Journal of Cancer Research and Clinical Oncology. 2019; 145: 2573–2582.

[20] Tsiambas E, Riziotis C, Mastronikolis NS, Peschos D, Mortakis A, Kyroysis G, et al. Comparative p16 IKN4A Expres-sion in Laryngeal Carcinoma and Cervical Cancer Precursors: A Real-time Grid-based Immunocytochemistry Analysis. Anti-cancer Research. 2018; 38: 5805–5810.

[21] O’Neill CJ, McCluggage WG. P16 expression in the female genital tract and its value in diagnosis. Advances in Anatomic Pathology. 2006; 13: 8–15.

[22] Song F, Du H, Xiao A, Wang C, Huang X, Yan P, et al. Evaluating the Performance of p16 INK4a Immunocytochemistry in Cervical Cancer Screening. Cancer Management and Research. 2020; 12: 9067–9075.

[23] Kudela E, Holubekova V, Farkasova A, Danko J. Determination of malignant potential of cervical intraepithelial neoplasia. Tumour Biology. 2016; 37: 1521–1525.

[24] Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, et al. Cervical cancer: screening, diagnosis and staging. Journal of B.U.ON. 2016; 21: 320–325.

[25] Buskwofie A, David West G, Clare CA. A Review of Cervical Cancer: Incidence and Disparities. Journal of the National Medical Association. 2020; 112: 229–232.

[26] Wuerthner BA, Avila Wallace M. Cervical cancer: Screening, management, and prevention. The Nurse Practitioner. 2016; 41: 18–23.

[27] Curty G, de Carvalho PS, Soares MA. The Role of the Cervicovaginal Microbiome on the Genesis and as a Biomarker of Premalignant Cervical Intraepithelial Neoplasia and Invasive Cervical Cancer. International Journal of Molecular Sciences. 2019; 21: 222.

[28] Kuo K, Chang H, Hsiao C, Lin M. Increased Ki-67 proliferative index and absence of P16INK4 in CIN-HPV related pathogenic pathways different from cervical squamous intraepithelial lesion. The British Journal of Ophthalmology. 2006; 90: 894–899.

[29] Mello V, Sundstrom RK. Cervical Intraepithelial Neoplasia. StatPearls Publishing: Treasure Island (FL). 2021.

[30] Sheu JJ, Guan B, Choi J, Lin A, Lee C, Hsiao Y, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. The Journal of Biological Chemistry. 2010; 285: 38260–38269.

[31] He J, Fu L, Li Q. Rsf‑1 regulates malignant melanoma cell viability and chemoresistance via NF‑κB/Bcl‑2 signaling. Molecular Medicine Reports. 2019; 20: 3487–3498.

[32] Tian J, Kong E, Wang X, Xie Z, Chang CY, Sheu JJ, Hao Q, Sun L. RSF-1 siRNA Enhances Tumor Radiosensitivity in Cervical Cancer via Enhanced DNA Damage, Cell Cycle Redistribution, and Promotion of Apoptosis. OncoTargets and Therapy. 2020; 13: 3061–3071.

[33] Sheu JJ, Choi JH, Guan B, Tsai F, Hua C, Lai M, et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. The Journal of Pathology. 2013; 229: 559–568.

[34] Yang L, Wang M, He P. LncRNA NEAT1 Promotes the Progression of Gastric Cancer Through Modifying the miR-1224-5p/RSF1 Signaling Axis. Cancer Management and Research. 2020; 12: 11845–11855.